<DOC>
	<DOCNO>NCT00028912</DOCNO>
	<brief_summary>RATIONALE : Bortezomib may stop growth tumor cell block enzymes necessary tumor cell growth . Drugs use chemotherapy carboplatin use different way stop tumor cell divide stop grow die . Bortezomib may help carboplatin kill tumor cell make tumor cell sensitive drug . PURPOSE : Phase I trial study effectiveness combine bortezomib carboplatin treat patient recurrent progressive ovarian epithelial , primary peritoneal , fallopian tube cancer .</brief_summary>
	<brief_title>Bortezomib Carboplatin Treating Patients With Recurrent Progressive Ovarian Epithelial , Primary Peritoneal , Fallopian Tube Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine maximum tolerate dose bortezomib combination carboplatin patient recurrent progressive ovarian epithelial , primary peritoneal , fallopian tube cancer . - Determine toxicity regimen patient . - Determine pharmacodynamics regimen patient measurement 20S proteasome inhibition whole blood . - Correlate toxicity 20S proteasome inhibition whole blood assay patient treat regimen . OUTLINE : This dose-escalation study bortezomib . Patients receive carboplatin IV 30 minute day 1 8 follow 1 week rest first course treatment . Beginning second course , patient receive bortezomib IV day 1 , 4 , 8 , 11 carboplatin IV 30 minute day 1 8 . Treatment repeat every 21 day 6 course absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos bortezomib maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . Once MTD determine , 8 additional patient accrue treated dose . PROJECTED ACCRUAL : A total 3-32 patient accrue study .</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Fallopian Tube Neoplasms</mesh_term>
	<mesh_term>Peritoneal Neoplasms</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm ovarian epithelial , primary peritoneal , fallopian tube cancer Recurrent progressive disease Received least 1 prior platinumbased chemotherapy regimen contain carboplatin , cisplatin , another organoplatinum compound primary disease May include highdose therapy , consolidation , extend therapy surgical nonsurgical assessment No brain metastasis leptomeningeal involvement PATIENT CHARACTERISTICS : Age : Not specify Performance status : Karnofsky 70100 % Life expectancy : Not specify Hematopoietic : Absolute neutrophil count least 1,000/mm^3 Platelet count least 100,000/mm^3 Hemoglobin least 8.0 g/dL Hepatic : AST ALT great 2.5 time upper limit normal Bilirubin great 1.8 mg/dL Renal : Creatinine great 1.5 mg/dL Cardiovascular : LVEF great 50 % radionuclide ventriculogram twodimensional echocardiogram No peripheral vascular disease require surgical management No prior myocardial infarction No congestive heart failure No orthostatic hypotension No acute ischemia significant conduction abnormality ( bifascicular block , define leave anterior hemiblock right bundle branch block , second third degree AV block ) evidence electrocardiogram No prior cerebrovascular event Other : No peripheral neuropathy grade 2 great No serious medical psychiatric illness Not pregnant Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : See Disease Characteristics No 2 prior regimens recurrent disease , include 1 nonplatinum contain regimen At least 4 week since prior chemotherapy ( 6 week nitrosoureas mitomycin ) recover Endocrine therapy : At least 1 week since prior hormonal therapy direct primary tumor Concurrent hormone replacement therapy allow Radiotherapy : Not specify Surgery : See Disease Characteristics At least 2 week since prior major surgery</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2004</verification_date>
	<keyword>recurrent ovarian epithelial cancer</keyword>
	<keyword>primary peritoneal cavity cancer</keyword>
	<keyword>fallopian tube cancer</keyword>
</DOC>